Healthcare Professionals
Benefits of CGM
SEVEN System Tutorial
DexCommunity
DexCom Delivers
Need CME?
Downloadable Product Info

Clinical Validation

Proven efficacy

Clinical studies show that SEVEN® users:1,3-6
  • Are able to reduce time spent in hyperglycemia and hypoglycemia, while simultaneously increasing time spent in their target glucose range
  • Achieve statistically significant improvements in glycemic profiles, even without guidance or therapeutic adjustments from physicians
  • Achieve improvements in glycemic control (whether previously having good or poor control)
All CGMs are not created equal

To learn more, click one of the topics below:

On-time performance

SEVEN PLUS offers proven consistent performance, even during rapid rates of glucose change. Other systems warn about calibration during glucose fluctuations and restrict patients to calibrate only during times of stable blood glucose — a big inconvenience. The SEVEN PLUS lets patients calibrate on their own terms.

DexCom data shows that the difference between its Sensor and fingerstick readings (known as lag-time) is 5 minutes on average. The SEVEN PLUS will deliver more robust glucose data and fewer data gaps, giving patients confidence to trust their trend.

Performance During Change

Back to top


Clinical evidence of patient benefits

A growing body of research is showing that CGM can provide short- and long-term clinical benefits to a wide group of patients.1-11

Patients Who Could Benefit from CGMgrades

Back to top


Download a CGM clinical reference sheet

Back to top


References:
  1. Zisser H, et al. Accuracy of a Seven-Day Continuous Glucose Sensor Compared to YSI Blood Glucose Values. 27th Workshop of the AIDPIT Study Group, 2nd European Diabetes Technology and Transplantation Meeting (EUDDT): Poster S 03. Jan 2008.
  2. Deiss D, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006;29(12):2730-2732.
  3. Garg S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006;29(1):44-50.
  4. Garg SK, et al. Continuous home monitoring of glucose: improved glycemic control with real-life use of continuous glucose sensors in adult subjects with type 1 diabetes. Diabetes Care. 2007;30(12):3023-3025.
  5. Bailey TS, et al. Reduction in hemoglobin A1c with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther. 2007;9(3):203-210.
  6. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2008) Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359(14):1464-1476.
  7. Standards of medical care in diabetes — 2009. American Diabetes Association. Diabetes Care. 2009;32 Suppl 1:S13-61.
  8. Waldron-Lynch F, et al. Continuous glucose monitoring: long live the revolution! Nat Clin Pract Endocrinol Metab. 2009;5(2):82-83.
  9. Kerssen, et al. Do HbA1c levels and the self-monitoring of blood glucose levels adequately reflect glycaemic control during pregnancy in women with type 1 diabetes mellitus? Diabetologia. 2006;49:25-28.
  10. Freeman, et al. The use of continuous glucose monitoring to evaluate the glycemic response to food. Diabetes Spectrum. 2008;21(2):134-137.
  11. Brownlee M, et al. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA. 2006;295(14):1707-1708.